§ 520.370 Cefpodoxime tablets.

(a) Specifications. Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount—(i) Dogs. Administer 10 mg per pound (lb) body weight twice daily orally.


(2) Indications for use—(i) Dogs. For the treatment of skin and soft tissue infections including cellulitis, pyoderma, dermatitis, wound infections, and abscesses due to susceptible strains of *Staphylococcus aureus*. For the treatment of genitourinary tract infections (cystitis) due to susceptible strains of *Escherichia coli*, *Proteus mirabilis*, and *S. aureus*.

(ii) Cats. For the treatment of skin and soft tissue infections including abscesses, wound infections, cellulitis, and dermatitis caused by susceptible strains of *Pasteurella multocida*, *S. aureus*, *Staphylococcus epidermidis*, and *Streptococcus* spp.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]

§ 520.370 Cefpodoxime tablets.

(a) Specifications. Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount—(i) Dogs. Administer 10 mg per pound (lb) body weight twice daily orally.


(2) Indications for use—(i) Dogs. For the treatment of skin and soft tissue infections including cellulitis, pyoderma, dermatitis, wound infections, and abscesses due to susceptible strains of *Staphylococcus aureus*. For the treatment of genitourinary tract infections (cystitis) due to susceptible strains of *Escherichia coli*, *Proteus mirabilis*, and *S. aureus*.

(ii) Cats. For the treatment of skin and soft tissue infections including abscesses, wound infections, cellulitis, and dermatitis caused by susceptible strains of *Pasteurella multocida*, *S. aureus*, *Staphylococcus epidermidis*, and *Streptococcus* spp.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[89 FR 52815, Aug. 30, 2004]
culturing and susceptibility tests on samples collected prior to treatment. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis. Not for animals that are raised for food production. Chloramphenicol should not be administered in conjunction with or 2 hours prior to the induction of general anesthesia with pentobarbital because of prolonged recovery. Chloramphenicol should not be administered to dogs maintained for breeding purposes. Because of potential antagonism, chloramphenicol should not be administered simultaneously with penicillin or streptomycin. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.390b Chloramphenicol capsules.
(a) Specifications. Each capsule contains 50, 100, 250, or 500 milligrams (mg) chloramphenicol.
(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.
1 Nos. 000069 and 050057 for capsules containing 50, 100, 200, or 500 mg chloramphenicol.
2 No. 058034 for capsules containing 100 or 250 mg chloramphenicol.
(c) Special considerations. Federal law prohibits the extralabel use of this product in food-producing animals.
(d) Conditions of use in dogs—(1) Amount. 25 milligrams per pound of body weight every 6 hours.
2 Indications for use. For treatment of bacterial pulmonary infections, bacterial infections of the urinary tract, enteritis, and infections associated with canine distemper caused by susceptible organisms. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.390c Chloramphenicol palmitate oral suspension.
(a) Specifications. Each milliliter contains chloramphenicol palmitate equivalent to 30 milligrams of chloramphenicol.
(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.
(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight every 6 hours. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.
(2) Indications for use. Treatment of bacterial pulmonary infections, infections of the urinary tract, enteritis, and infections associated with canine distemper that are caused by organisms susceptible to chloramphenicol.
(3) Limitations. Not for use in animals that are raised for food production. Must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.420 Chlorothiazide tablets and boluses.
(a) Specifications. Each tablet contains 0.25 gram of chlorothiazide.
(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.
(c) Conditions of use—(i) Amount. Usual dosage is 5 to 10 milligrams per pound of body weight two or three times daily.
(ii) Indications for use. For use in dogs for treatment of congestive heart failure and renal edema.
(iii) Limitations. (a) Dosage must be adjusted to meet the changing needs of the individual animal. In mild and responsive cases, it is suggested that a dose of 5 milligrams per pound of body weight be administered two or three times daily. In moderately edematous and moderately responsive animals, a dose of 7.5 to 10 milligrams per pound of body weight may be administered three times daily. Severe conditions may require higher doses. Certain animals may respond adequately to intermittent therapy; in these cases, the

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.